Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment

Sandra P. Smieszek*, Bart P. Przychodzen, Mihael H. Polymeropoulos

Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037, United States

A R T I C L E   I N F O
Article history:
Received 31 March 2020
Accepted 24 April 2020

A B S T R A C T
SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-CoV-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoV-ID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes).

We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson’s disease. It is available as a generic drug.

Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection.

© 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

1. Introduction

Recently a novel type of highly virulent beta-coronavirus was discovered in patients with pneumonia of unknown cause. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) as detected by sequencing of the samples was found to be the cause of a severe respiratory disease in humans [1]. The outbreak of COVID-19 resulted in a global epidemic with the number of confirmed cases surpassing 722,000 in March 2020. The SARS-CoV-2 genome shares about 80% similarity with SARS-CoV and is even more similar (96%) to the bat coronavirus RaTG13 [2]. Coronavirus are characterized by large genetic diversity and frequent recombination of their genomes, hence pose a challenge in terms of public health, currently based on 1455 viral genomes and predicted 24.5 genetic substitutions per year [3]. Understanding the mechanism of action of the virus is a fundamental step in delineating the optimal therapeutic agents. Similar to SARS-CoV, SARS-CoV-2 enters the cell by the means of binding of cellular receptor(s) including the Angiotensin-converting enzyme 2 (ACE2) membrane bound protein [4]. ACE2 is a type I membrane protein expressed in lungs, heart, kidneys and intestine and decreased expression of ACE2 is associated with cardiovascular diseases [2,5]. The structural basis for this recognition has been recently mapped out and the cryo-EM structure of the full length viral spike protein that targets human ACE2 complex has been reported [2]. The authors show that viral S protein binds ACE2 at least 10 times more tightly, when compared to the spike protein of the previous SARS-CoV strain. The viral spike glycoprotein (S protein) mediates receptor recognition [6]. Recently the 3.5-angstrom-resolution structure of the S protein has been described [6]. The S protein is cleaved into two subunits: S1 and S2. This cleavage of S protein by host proteases is critical for viral activation and subsequent infection [2].

Host protease dependence of SARS-CoV-2 entry is a critical step. SARS-CoV takes advantage of the endosomal cysteine proteases Cathepsin B and L (CTSL and CTSB) [7,8], Cathepsin L is a peptidase that preferentially cleaves peptide bonds with aromatic residues in
P2 and hydrophobic residues in P3 position [9]. CTSL is active at pH 3-6.5, in the presence of thiol and its enzymatic stability is dependent on ionic strength [9]. Cathepsin L proteolysis is a crucial mechanism for Ebola as well as SARS-CoV for processing of viral glycoprotein before cell membrane fusion [8]. Specifically, during cell membrane fusion the S protein is cleaved by host cell proteases, exposing a fusion peptide of the S2 domain. This leads to the fusion of viral and cellular membranes and the release of the viral genome into the cytoplasm of the host cell.

Cleavage of the S protein occurs between the S1 and S2 domains. Subsequently within the S2 domain additional cleavage (S2’) occurs. S2’ cleavage is responsible for unmasking and activating of the fusion peptide. Cleavage at both sites is believed to be necessary for viral entry by endocytosis into the host cell. The S1/S2 cleavage site of SARS-CoV-2 is between the threonine and methionine at positions 696 and 697. This S1/S2 cleavage site is identical to that of SARS-CoV which has been shown to be cleaved by Cathepsin L (CTSL), a lysosomal cystein protease encoded by the CTSL1 gene. SARS-CoV-2 also has a furin-like protease cleavage site not found in SARS-CoV, between the arginine and serine at positions 685 and 686. This site may be cleaved by furin during viral egress. The S protein of SARS-CoV-2 might be also primed by Transmembrane protease, serine 2 (TMPRSS2) [4]. Inhibition of TMPRSS2 has been shown to suppress SARS-CoV infection. High expression of TMPRSS2 correlates with SARS-CoV infection in the upper lobe of the lung [10]. Interfering with the spike protein processing by the host cell, whether by affecting the environment or modulating gene expression levels, hence offers a potential therapeutic strategy.

Genetic variation in CTSL gene could in theory affect the propagation capacity of the virus. Furthermore CTSL polymorphisms could affect the susceptibility to SARS-CoV-2 where for example individuals with certain genetic variant have reduced expression of Cathepsin L and in turn could be protected or have lower viral titers. Additionally, elements of hosts major histocompatibility complex I (MHC I) and cytotoxic T cell lymphocytes (CTL) mediated immune responses might affect viral proliferation [11]. There are susceptibility factors spanning from ethnicity background to age related groups, to comorbid conditions [12].

Novel therapeutics identified by high throughput screening assay, shown to block the cleavage of CoV2 S (Spike) protein by Cathepsin L,Cathepsin B or TMPRSS2 (or any other protease) at predicted/selected binding sites, will be a viable approach to functionally target and limit SARS-CoV-2 virus. Other therapeutic mechanisms of action could involve lowering or modulating the expression of CTSL or affecting the conditions of the CTSL lysosomal environment by modulating pH. Here we tested compounds that could help identify potential therapeutic agents with the capacity to decrease expression or inhibit the expression of the CTSL gene. We identify Amantadine among top significant compounds. Further clinical studies should be conducted to examine whether amantadine could be useful in treating patients with COVID-19 infection.

2. RESULTS

2.1. Drugs screening

To discover potential, pharmaceutical agents capable of affecting transcriptional expression levels of CTSL implicated in SARS-CoV and SARS-CoV2 patho-physiology, we have screened 466 compounds belonging to 14 different therapeutic classes. Screening was conducted using human retinal pigment epithelia cell line (ARPE-19) and gene expression changes were collected across 12,490 genes. The ARPE-19 cell line was initially selected as a well suited model for the study of compounds that affect neuronal type cells, in particular anti-psychotics. ARPE-19 expresses a variety of well known, neuronal, cell surface receptors that include the dopamine receptor D2, the serotonin receptors 1A, 2A, and 2C, the muscarinic receptor M3, and the histamine receptor H1. Here, we describe the discovery of a CTSL/B, lysosomotropic signature which might give insights into the therapeutic potential of the tested compounds.

We analyzed the expression profiles of CTSL across all 466 compounds tested. In order to find positive hits we selected only those results that showed a reduction of expression of CTSL (1.5 -fold difference). There were no drugs that would decrease CTSL expression by more than 40%. Between the most 5 potent compounds (Table 1) were drugs from various therapeutic areas – muscle relaxer, antihistamine, anti-epileptic, anticholergic and antiviral. These top results (top 5 of 466) included, Amantadine hydrochloride, a known and safe antiviral agent that was previously used to treat patients with influenza A.

Amantadine due to its high lipophilicity, can pass through lysosome membranes and accumulate in lysosomes acting at a higher micromolar concentrations as lysosomotropic alkalining agent [13,14]. Amantadine inhibits influenza A replication at low micromolar concentration, by blocking M2 ion channel protein which acidifies virus interior and releases its nucleoprotein [13,14,15]. It causes pH reduction which abrogates membrane fusion a necessary step for virus replication [13,14]. Other lysosomotropic drugs affect lysosomes through lysosome membrane permeabilization and accumulation also blocking of Ca2+ signaling, and enzyme activity inhibition or storage material accumulation [16]. Since amantadine behaves as a lysosomotropic substance that passes easily through the lysosome membrane of SARS-CoV-2 virus and accumulates in it, it could lower the pH of lysosome thus inhibit the protease activities [17]. Moreover amantadine may directly affect viral entry by down-modulating CTSL and other lysosomal pathway genes. The PK profile of the drug makes it particularly suitable for administration to humans. Plasma concentration is in the range of 200-800ng/mL depending on the formulation and dosing regimen. Plasma half-life is 17 hours (range: 10 to 25 hours) with renal clearance as main elimination mechanism. Amantadine HCl immediate release is available as a 100-mg tablet and 50 mg/5 mL syrup and is typically administered twice daily [18]. Human cells in tissue culture readily tolerated amantadine up to a concentration of 100 µg/mL (~657uM).

Since CTSL was not the top differentially expressed transcript, we decided to extend our analysis to all the genes that were down-regulated by amantadine. Among the top 500 differentially expressed probes (383 genes, all with at least 50% expression reduction) we have found 21 genes were related to lysosomal terms using David Enrichment [19] tool (GO:005764, p=2.49 × 10-3). Moreover, the top significant pathway by ENRICHR enrichment analysis tool was KEGG lysosome pathway. Amantadine’s significant effect upon lysosome pathway genes is shown on Fig. 1 and Table 2 and Table 3. Fig. 1 displays notable difference in over-representation of genes with downregulated expression across lysosome pathway genes. Table 2 displays top lysosomal ontology terms over-represented among transcriptionally downregulated genes treated with amantadine. Table 3 displays top lysosomal expression probes downregulated post treatment with amantadine.

We investigated natural variation of CTSL expression across ethnicities, focusing on common and rare variants. The Genotype-Tissue Expression (GTEx) project [5] provides genotype information and gene expression levels across 49 human tissues from 838 donors, allowing us to examine the expression patterns of CTSL, both across tissues as well as across individuals. Fig. 2 shows expression of CTSL across different organs and associated cell types. CTSL is widely expressed in many crucial organs (increase expression in: lungs, in nerve-tibial, adipose, artery, whole blood and fibroblasts). Looking at expression quantitative trait loci
Table 1
List of top drugs affecting transcriptional CTSL downregulation (log2 of normalized Affymetrix probe intensity)

| DrugID       | log2(treated) CTSL | log2(control) CTSL | log2 difference |
|--------------|-------------------|-------------------|-----------------|
| Baclofen     | 9.58              | 10.40             | -0.82           |
| Triprolidine Hydrochloride | 9.54              | 10.33             | -0.79           |
| Brompheniramine Maleate | 9.57              | 10.33             | -0.75           |
| Amantadine Hydrochloride | 9.62              | 10.33             | -0.70           |
| Phenytion    | 9.56              | 10.26             | -0.70           |
| Atropine Sulfate | 9.63              | 10.33             | -0.70           |

Fig. 1. Notable difference in over-representation of genes with downregulated expression across lysosome pathway genes. Black columns represent average expression levels of amantadine treated samples, gray columns represent average expression levels of control samples. Y-axis represents Affymetrix probe intensity associated with expression.

Table 2
Top lysosomal ontology terms over-represented among transcriptionally downregulated genes treated with amantadine.

| Term          | Count (n) | % Pathway | Fold Enrichment | P-value  | P-value Bonferroni | P-value FDR   |
|---------------|-----------|-----------|-----------------|----------|--------------------|--------------|
| GO:0005764-lysosome | 21       | 5.19      | 4.42            | 6.65E-08 | 2.49E-05           | 9.19E-05     |
| Lysosome      | 19        | 4.69      | 3.75            | 3.77E-06 | 0.001389           | 0.005193     |
| hsa04142:Lysosome | 14       | 3.46      | 4.37            | 1.55E-05 | 0.003425           | 0.019698     |

Table 3
Top lysosomal expression probes downregulated post treatment with amantadine.

| Gene Name | Affymetrix Probe ID | Mean amantadine treated expression (log2) | Mean control expression (log2) | Mean expression difference (log2) |
|-----------|---------------------|------------------------------------------|-------------------------------|---------------------------------|
| CTSH      | 202295_s_at         | 9.62                                     | 12.13                         | -2.51                           |
| GALK      | 204417_at           | 6.58                                     | 8.64                          | -2.06                           |
| RNASET2   | 217983_s_at         | 8                                        | 9.82                          | -1.81                           |
| CTSDK     | 202450_s_at         | 7.09                                     | 8.9                           | -1.81                           |
| GA1       | 201667_at           | 11.23                                    | 12.99                         | -1.76                           |
| CLN5      | 204085_s_at         | 5.93                                     | 7.67                          | -1.74                           |
| SCARB2    | 201647_s_at         | 6.97                                     | 8.6                           | -1.63                           |
| AGA       | 204333_s_at         | 6.57                                     | 8.17                          | -1.6                            |
| CLN5      | 214252_s_at         | 6.13                                     | 7.71                          | -1.57                           |
| MAR3      | 213256_at           | 5.55                                     | 7.12                          | -1.57                           |
| PCYOX1    | 203803_at           | 7.15                                     | 8.71                          | -1.57                           |
| CPQ       | 203501_s_at         | 6.41                                     | 7.96                          | -1.55                           |
| CTSB      | 213274_s_at         | 7.75                                     | 9.23                          | -1.48                           |
| STS       | 203767_s_at         | 5.55                                     | 7.02                          | -1.47                           |
| LAMP1     | 201551_s_at         | 7.87                                     | 9.27                          | -1.4                            |
| AGA       | 204332_s_at         | 9.18                                     | 10.57                         | -1.39                           |
| AGA       | 216064_s_at         | 8.12                                     | 9.5                           | -1.38                           |
| PSAP      | 200866_s_at         | 10.59                                    | 11.95                         | -1.36                           |
| LGMN      | 201212_at           | 8.33                                     | 9.68                          | -1.35                           |
| CPQ       | 208454_s_at         | 7.3                                      | 8.65                          | -1.34                           |
| CD164     | 208654_s_at         | 8.7                                      | 10.04                         | -1.34                           |
| CTSB      | 218924_s_at         | 6.59                                     | 7.91                          | -1.32                           |
| RAB38     | 219412_at           | 6.51                                     | 7.81                          | -1.3                            |
| GNS       | 212334_at           | 9.71                                     | 10.97                         | -1.27                           |
| BCL10     | 205263_at           | 7.44                                     | 8.69                          | -1.25                           |
Fig. 2. Normalized Expression of Cathepsin L (CTSL) across tissues between females (red) and males (blue) log10(TPM) (x-axis log10 of Transcripts per Million, plus one).
(eQTLs) in CTLs, we have found a very significant and lung specific (rs2378757) variant conferring highly variable expression. The genotype (Supplementary Figure 1a) confers lower baseline expression and is likely associated with a better response and conversely higher expression perhaps higher viral load. In addition, there are several splice quantitative trait loci (sQTLs) (hence variants affecting splicing ratios of transcripts) such as rs114063116 significant and present in the lungs tissue. CTL genotype-tissue analysis points to potential variants that may constitute susceptibility or resilience to infection of SARS-CoV-2 in certain individuals. Interestingly, the alternative splicing of the CTL transcript in the lung further displays tissue specific regulatory programs (Supplementary Figure 1b). A recent functional study points to a common variant in CTL in the proximal CTL1 promoter, (position C-171A), confirmed to alter transcription via alteration of the xenobiotic response element [20]. This and similar other variants likely affect natural diversity in baseline expression hence viral fitness at cell entry of SARS-CoV-2. Additionally, we checked in the gnomAD [21] database the number of rare variants and variation tolerance status of CTLs. The results show that there are on average 167 missense variants in CTL and the gene is predicted to be loss-of-function variant tolerant with a pLI of 0.01. Together with significant eQTLs this indicates large effect of genetic variation on CTL expression. TMPRSS2 is also widely expressed in multiple tissues including those in the GI system, lung, and kidney [5]. The high expression of CTL and TMPRSS2 transcripts in a series of organs could explain the viral manifestation in these tissues such as recent studies showing viral presence in stool samples from infected individuals as well as effects of the virus seen across multiple tissues [22].

3. Discussion

Decreasing the expression of CTLs is likely a potential mechanism that would lower the capacity of the virus to enter the next host cell. Another symbiotic, therapeutic mechanism is lysosomal pH modulation that would further interfere with proteolytic Spike protein activation. Therapeutic agents capable of perturbing the lysosomes, their function or microenvironment may offer protection from the virus or decrease the severity of the symptoms. Given that amantadine does not only down-regulate CTL expression, but a number of key lysosomal enzymes, we can now hypothesize that lysosomal dysfunction induced by amantadine administration can be protective against viral entry and ultimately replication. Our hypothesis is that people with certain lysosomal storage diseases are resistant to one of these viruses. Along these lines there is suggestive evidence for this to be true. For example Niemann-Pick disease type C1 lipid storage disorder offers resistance to Ebola in patient cell lines [23,24]. Interestingly, bat species show selective sensitivity to Ebola versus Marburg viruses [25]. The differences are primarily due to amino acid differences in NPC1 protein indicating that the heterogeneity of bat NPC1 orthologs is a crucial factor affecting varied degree of susceptibility [25].

Interfering with the lysosomal milieu can have protective effects from coronavirus which we know uses Cathepsin L, a pH sensitive enzyme, to process the cleavage of the spike protein. Amantadine would be predicted by physical and chemical properties to accumulate in the lysosomes and raise pH, interfering with cathepsin L function. The gene expression pattern reported in this paper suggests that a more general lysosomal program is down-regulated by Amantadine, likely through a common set of transcription factors. Additionally, amantadine’s property to accumulate in lysosomes, if effective, could reduce viral load, decrease intra-host organ spread and decrease individual-patient, associated disease severity and progression. Importantly, the dose that was tested in High Throughput Screen Assay is within one order of magnitude of expected pharmacokinetic, clinical profile (~5μM). That would mean the drug can be administered per existing, safe and approved label dosing.

Further studies including clinical trials would be required in order to examine the role of amantadine administration as a treatment for COVID-19.

4. Materials and Methods

4.1. Cell culture and drug treatment

Drugs screening was carried out, the same one as applied in our previous study [26]. The retinal pigment epithelia cell line, ARPE-19/HPV-16, was chosen to establish a database of drug profiles because of its non-cancerous, human origin, with a normal karyotype. It can also be easily grown as monolayer in 96-well plates. Compounds were obtained from Sigma (St. Louis, MO) or Vanda Pharmaceuticals (Washington, DC). Cells were aliquoted on 96-well plates (~2×10e5 cells/well) and incubated for 24 h prior to providing fresh media with a drug, or the drug vehicle (water, dimethyl sulfoxide, ethanol, methanol, or phosphate-buffered saline solution). Drugs were diluted 1000 fold in buffered in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (D-MEM/F-12) culture medium (Invitrogen, Carlsbad, CA) containing nonessential amino acids and 110 mg/L sodium pyruvate. In these conditions, no significant changes of pH were expected, which was confirmed by the monitoring of the pH indicator present in the medium. A final 10 μM drug concentration was chosen because it is believed to fit in the range of physiological conditions [26]. Microscopic inspection of each well was conducted at the end of the treatment to discard any samples where cells had morphological changes consistent with apoptosis. We also verified that the drug had not precipitated in the culture medium.

4.2. Gene expression

Cells were harvested 24 h after treatment and RNA was extracted using the RNeasy 96 protocol (Qiagen, Valencia, CA). Gene expression for 22,238 probe sets of 12,490 genes was generated with U133A2.0 microarrays following the manufacturer’s instructions (Affymetrix, Santa Clara, CA). Drugs were profiled in duplicate or triplicate, with multiple vehicle controls on each plate. A total of 708 microarrays were analyzed including 74 for the 18 antipsychotics, 499 for the other 448 compounds, and 135 for vehicle controls. The raw scan data were first converted to average difference values using MAS 5.0 (Affymetrix). The average difference values of both treatment and control data were set to a minimum of 50 or lower. For each treatment category, all probe sets were then ranked based on their amplitude, or level of expression relative to the vehicle control (or the average of controls was selected when more than one was used). Amplitude was defined as the ratio of expression (t−v) / [(t+v) / 2] where t corresponds to treatment instance and v to vehicle instance. Each drug group profile was created using our novel Weighted Influence Model, Rank of Ranks (WIMRR) method which underscores the rank of each probe set across the entire gene expression profile rather than the specific change in expression level. WIMRR takes the average rank of each probe set across all of the members of the group and then reranks the probe sets from smallest average rank to largest average rank. A gene-set enrichment metric based on the Kolmogorov–Smirnov (KS) statistic. Specifically, for a given set of probes, the KS score gives a measure of how up (positive) or down (negative) the set of probes occurs within the profile of another treatment instance.
Acknowledgements

We thank all the reviewers for valuable comments and suggestions.

Declarations

Funding: Vanda Pharmaceuticals

Competing Interests: None

Ethical Approval: Not required

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijantimicag.2020.106004.

References

[1] Zhu N, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–33.
[2] Yan R, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 2020. doi:10.1126/science.abb2762.
[3] Hufnfield J, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 2018;34:4121–3.
[4] Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;0.
[5] Lonsdale J, et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 2013;45:580–5.
[6] Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260–3.
[7] Simmons G, et al. Inhibitors of cathepsin L prevent severe acute respiratory coronavirus entry. Proc. Natl. Acad. Sci. 2005;102:11876–81.
[8] Elshabrawy HA, et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 2014;88:4353–65.
[9] Kirschke H, Cathepsin L, Handb. Proteolytic Enzym. 1808–1817 2013. doi:10.1016/B978-0-12-382219-2.00410-5.
[10] Matsuyma S, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010;84:12658–64.
[11] Herzt C, et al. An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design. bioRxiv 2020 2020.02.25.963546. doi:10.1101/2020.02.25.963546.
[12] Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res. Ther. 2010;12:R85.
[13] Krammer F, et al. Influenza. Nat. Rev. Dis. Prim. 2018;4:1–21.
[14] Kolocouris A, et al. Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A. J. Med. Chem. 2014;57:4629–39.
[15] Ma C, et al. Identification of the functional core of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 2009;106:12283–8.
[16] Pisonero-Vaquero S, Medina DL. Lysoosmotic Drugs: Pharmacological Tools to Study Lysosomal Function. Curr. Drug Metab. 2018;18:1147–58.
[17] Duff KC, Cudmore AJ, Bradshaw JP. The location of amantadine hydrochloride and free base within phospholipid multilayers: a neutron and X-ray diffraction study. Biochim. Biophys. Acta - Biomembr. 1993;1145:149–56.
[18] deVries T, Dentiste A, Handiwala L, Jacobs D. Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies. Neurol. Ther. 2015;8:449–60.
[19] Smedley D, et al. The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Res 2015;43:W589–98.
[20] Mbewe-Campbell N, et al. Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J. Hypertens. 2012;30:1961–9.
[21] Karczewski KJ, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv 2019;531210. doi:10.1101/531210.
[22] Hendeon J. COVID-19: faecal–oral transmission? Nat. Rev. Gastroenterol. Hepatol. 2020 pp. 1–1. doi:10.1038/s41575-020-0295-7.
[23] Witbrock K, et al. Genetic diseases conferring resistance to infectious diseases. Genes Dis 2015;2:247–54.
[24] Haines KM, Vande Burgt NH, Francica JR, Kaletsky RL, Bates P. Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression. Virology 2012;432:20–8.
[25] Takadate Y, et al. Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism. Cell Rep 2020;30:308–319.e5.
[26] Polymeropoulos MH, et al. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr. Res. 2009;108:134–42.